RESEARCH

Our lab employs genomic, computational, and functional methods to study the lung cancer transcriptome, focusing on both coding (mRNA) and non-coding (microRNA) regions. Our goal is to identify biomarkers that can improve diagnosis and guide the selection of optimal therapeutics. In the post-genomic era, we are now able to analyze the molecular profiles of various cancer types. Using multi-omics approaches, we have discovered that seemingly identical lung tumors can be distinguished by specific molecular features, known as molecular subtypes. These subtypes influence how the tumor responds to treatment and its potential for metastasis. Additionally, we have explored the circulating miRNome in the blood of lung cancer patients and identified valuable biomarkers for early diagnosis. Our findings also suggest that circulating microRNAs act as molecular messengers, transferring information between tumor cells and the tumor microenvironment (or vice versa), which plays a key role in lung cancer progression.

Understanding both the coding and non-coding transcriptomes in lung cancer will undoubtedly facilitate earlier detection of tumor lesions and the development of more effective treatment strategies.